[go: up one dir, main page]

MX2019001979A - Agonista de ppar? para el tratamiento de neoplasias hematicas. - Google Patents

Agonista de ppar? para el tratamiento de neoplasias hematicas.

Info

Publication number
MX2019001979A
MX2019001979A MX2019001979A MX2019001979A MX2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A MX 2019001979 A MX2019001979 A MX 2019001979A
Authority
MX
Mexico
Prior art keywords
treatment
blood cancers
ppary agonist
ppary
agonist
Prior art date
Application number
MX2019001979A
Other languages
English (en)
Inventor
Mantzoros Christos
Original Assignee
Intekrin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intekrin Therapeutics Inc filed Critical Intekrin Therapeutics Inc
Publication of MX2019001979A publication Critical patent/MX2019001979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos de tratamiento de cánceres de sangre incluyendo leucemia y mieloma con el compuesto de fórmula (I) conocido como INT131: (ver Fórmula).
MX2019001979A 2016-08-18 2017-08-18 Agonista de ppar? para el tratamiento de neoplasias hematicas. MX2019001979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Publications (1)

Publication Number Publication Date
MX2019001979A true MX2019001979A (es) 2019-09-19

Family

ID=61197183

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001979A MX2019001979A (es) 2016-08-18 2017-08-18 Agonista de ppar? para el tratamiento de neoplasias hematicas.

Country Status (12)

Country Link
US (1) US20210379049A1 (es)
EP (1) EP3500268A4 (es)
JP (2) JP2019524888A (es)
KR (1) KR20190064573A (es)
CN (1) CN110461329A (es)
AU (1) AU2017313839A1 (es)
BR (1) BR112019003130A2 (es)
CA (1) CA3034258A1 (es)
EA (1) EA201990512A1 (es)
MX (1) MX2019001979A (es)
SG (2) SG11201901320WA (es)
WO (1) WO2018035446A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017019170A2 (pt) 2015-03-09 2018-07-10 Intekrin Therapeutics, Inc. métodos para o tratamento de doença do fígado gorduroso não alcoólico e / ou lipodistrofia
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
EP3976037A1 (en) * 2019-05-30 2022-04-06 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3018186B1 (ja) * 1999-03-09 2000-03-13 大阪大学長 抗炎症剤、単球系細胞の増殖抑制剤
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物
AU2014212740B2 (en) * 2013-01-30 2015-12-24 Intekrin Therapeutics, Inc. PPARy agonists for treatment of multiple sclerosis
MY195671A (en) * 2016-06-08 2023-02-03 Support Venture Gmbh Pharmaceutical Combinations for Treating Cancer

Also Published As

Publication number Publication date
CA3034258A1 (en) 2018-02-22
EA201990512A1 (ru) 2019-08-30
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
WO2018035446A1 (en) 2018-02-22
SG10202101501PA (en) 2021-03-30
EP3500268A4 (en) 2020-04-15
JP2019524888A (ja) 2019-09-05
KR20190064573A (ko) 2019-06-10
EP3500268A1 (en) 2019-06-26
JP2022116304A (ja) 2022-08-09
SG11201901320WA (en) 2019-03-28
CN110461329A (zh) 2019-11-15
US20210379049A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
ZA202307128B (en) Anti-cd38 antibodies for treatment of acute myeloid leukemia
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
UA123201C2 (uk) Спосіб отримання сполуки діарилтіогідрантоїну
PH12015502248A1 (en) 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2021015102A (es) Inhibidores del receptor del factor estimulante de colonias 1 (csf-1r).
MX2019001979A (es) Agonista de ppar? para el tratamiento de neoplasias hematicas.
PH12017501879A1 (en) Methods for treating cancer
MX366765B (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerósis múltiple.
TN2019000211A1 (en) Antitumoral compounds
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
HK1232240A1 (zh) 急性骨髓性白血病 等幾種血液腫瘤的新型免疫療法
EA201992557A1 (ru) Противоопухолевые соединения
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями